Latest EYLEA 8mg (Aflibercept 8mg) Data & Publications
Explore recent clinical and real-world evidence supporting treatment outcomes in retinal disease.
One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report
Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M. Ophthalmol Ther. 2026 Feb 3. doi: 10.1007/s40123-025-01305-w. Epub ahead of print.
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report
Jan Spindler, Dmitri Artemiev, Isabel B Pfister, Christin Schild, Anne Tillmann, Katharina Heck, Felix Gabathuler, Ludovico Ruscitti, Tahm Spitznagel, Konstantinos Kitsos-Kalyvianakis, Marion R Munk, Katja Hatz, Sandrine A Zweifel, Gabriela Grimaldi, Gábor Márk Somfai, Aude Ambresin, Andreas Weinberger, Chiara M Eandi, Nicolas Feltgen, Alice Kitay, Andreas Ebneter, Justus G Garweg
SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration
Bailey C, Lange C, Chaudhary V, Lanzetta P, Oubraham H, Kirchner M, Machewitz T, Allmeier H, Zhang X, Hasanbasic Z, Munk MR; SPECTRUM study investigators. Eye (Lond). 2026 Jan 30. doi: 10.1038/s41433-026-04260-3. Epub ahead of print.
Please note, the SPECTRUM study was sponsored by Bayer AG. Data reported in the study were first presented at ARVO 2025.
Differentiating treatment episodes from gaps in eyes with diabetic macular oedema
Yohei Hashimoto, Adrian Robert Hunt, Rufino Silva, Antonella Witmer, Wajiha Jurdi Kheir, Francesco Viola, Maite Arrazola, Mohamed Moghazy Mahgoub, Andreas Pollreisz, Zanne Harvey, Daniel Barthelmes, Mark C Gillies
Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial
Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, Ricci F, Zhang X, Machewitz T, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Iida T; PULSAR Study Investigators. JAMA Ophthalmol. 2025 Dec 18. Doi: 10.1001/jamaophthalmol.2025.5098. Epub ahead of print.
Please note, the PULSAR study and this post hoc analysis were sponsored by Bayer AG and cofounded by Regeneron Pharmaceuticals Inc.
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial
Jean-François Korobelnik, Paolo Lanzetta, Sergio Leal, Frank G Holz, W Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J Berliner, Andrea Schulze, Min Zhao, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Peter Morgan-Warren, Zoran Hasanbasic, Robert Vitti, Karen W Chu, Kimberly Reed, Rafia Bhore, Yenchieh Cheng, Zhanying Bai, Boaz Hirshberg, George D Yancopoulos, Tien Y Wong; PULSAR Investigators DOI: 10.1016/j.ophtha.2025.08.022
Please note, this study was funded by Regeneron Pharmaceuticals, Inc., and co funded by Bayer AG.
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial
Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD; PHOTON investigators. Ophthalmology. 2025 Nov 10:S0161-6420(25)00707-9. doi:10.1016/j.ophtha.2025.10.028. Epub ahead of print.
Please note, this study was funded by Regeneron Pharmaceuticals, Inc., and co funded by Bayer AG.
PBS Information: EYLEA 8 mg: Authority required for the treatment of wet age-related macular degeneration and diabetic macular oedema. |
|---|
Please review the full product information before prescribing. Approved PI available here or upon request from Bayer Medical Information on 1800 008 757.
PP-EYL_8mg-AU-0373-1 Prepared Aug 2026